Track 1 - Gastroenterology & Hepatology
The study of the oesophagus, stomach, small intestine, pancreas, gallbladder, bile ducts, and liver is known as gastroenterology. This covers prevalent and serious conditions such colon polyps, cancer, hepatitis, gastroesophageal reflux disease (heartburn), stomach ulcers, colitis, gallbladder disease, malnutrition, irritable bowel syndrome, and pancreatitis. It involves a detailed analysis of the normal function (physiology) of the gastrointestinal organs, including material flow through the stomach and digestive system, nutrient absorption and retention in the body, waste disposal from the body, and the liver's role as a digestive organ.
Hepatology is the branch of medicine that incorporates the study of liver, gallbladder, biliary tree, and pancreas function as well as management of their disorders. The study of these organ deals with the understanding of clinical syndrome of non-cirrhotic portal hypertension and Congenital Hepatic Fibrosis; study the biological processes underlying the development of hepatic regeneration and study aspects of viral hepatitis that allow insight into disease mechanisms.
Track 2: Gastrointestinal Diseases
Gastrointestinal Sicknesses are issues of the digestive tract, that's from time to time known as the gastrointestinal (GI) tract. In digestion, food and drinks are damaged down into small parts (known as nutrients) that the frame can take in and use as strength and constructing blocks for cells. The digestive tract is made of the oesophagus (meals tube), stomach, massive and small intestines, liver, pancreas, and the gallbladder.
Sicknesses of the digestive gadget include:
-
Irritable bowel syndrome (IBS)
-
Inflammatory bowel disease (IBD)
-
Gastro oesophageal reflux disease (GERD)
-
Celiac disease
Track 3: Paediatric Gastroenterology
Digestive, liver, and nutritional problems in children often are quite different from those seen in adults. Specialized training and experience in Paediatric gastroenterology are important. Paediatric gastroenterologists treat children from the new-born period through the teen years. They choose to make paediatric care the core of their medical practice, which provides extensive experience specifically in the care of infants, children, and teens. We most commonly see children who complain of nausea, vomiting, diarrhoea, constipation, soiling or stool incontinence, abdominal pain, unexplained weight loss, liver disease or elevated liver tests and congenital anomalies of the GI tract.
Track 4: Neuro Gastroenterology
Neuro gastroenterology encompasses the study of the brain, the gut, and their interactions with relevance to the understanding and management of gastrointestinal motility and functional gastrointestinal disorders. Specifically, Neuro gastroenterology focuses on the functions, malfunctions and the malformations of the sympathetic, parasympathetic, and enteric divisions of the digestive tract. Disorders related to gastrointestinal motility (the movement of food contents through the GI tract) and gastric acid production are among the most common problems in the field of Gastroenterology and indeed, in all of medicine.
Track 5: Cellular & Molecular Gastroenterology
Metaplasia, the procedure in which one kind of grown-up tissue replaces another, is a result of endless tissue injury in the throat, gastroesophageal reflux sickness (GERD) is the condition that incessantly harms the squamous epithelium and causes its substitution by the intestinal-sort, columnar epithelium of Barrett's oesophagus. The cell of beginning for this columnar metaplasia stays obscure, yet various competitors have been proposed. For instance, GERD may cause develop oesophageal squamous cells to change into columnar cells (Trans differentiation) or invigorate juvenile oesophageal forebear cells (in the squamous epithelium or in the channels of oesophageal sub mucosal organs) to separate unusually into Short-entrail disorder (SBS) happens after a long surgical resection of small digestive system
Track 6: Gastrointestinal Cancers
Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion, including the oesophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The symptoms relate to the organ affected and can include obstruction (leading to difficulty swallowing or defecating), abnormal bleeding or other associated problems. The diagnosis often requires endoscopy, followed by biopsy of suspicious tissue. The treatment depends on the location of the tumour, as well as the type of cancer cell and whether it has invaded other tissues or spread elsewhere. These factors also determine the prognosis.
Track 7: Gastrointestinal Transplantation
Organ transplantation is a boon to the mankind whose internal organs have started to deteriorate and is no longer functioning. Although, with the regular lifestyle changes and the disease progression, the patients requiring transplant is ever increasing while the organ donors are lesser in number. Transplantation is recommended only when the organ has stopped responding to the treatments and is almost failing. Most of the organs in the gastrointestinal tract can be transplanted. For being eligible to be able to receive a transplanted organ, one should be able to satisfy all the required regulations set by the transplantation committee. The major gastrointestinal transplantations are liver, pancreas, oesophagus, small intestine, and colon. The transplantation is a major surgery, and so the patient has to be under observatory before and after the transplantation. Most of the times, the complications arise after the operation, where the body starts rejecting the graft or the organ. The complications if any can be diagnosed through haematological or imaging tests.
Track 8: Gastrointestinal Diseases during Pregnancy and Lactation
Febrile illness along with acute intestinal infections may in some cases cause miscarriage or premature labour. Certain infections have been reported to have caused miscarriage; however, there is no concrete evidence of common gastrointestinal disorders to cause miscarriage or premature labour. If the infection progresses to a critical stage, the foetus is at high risk from both the infection and also the subsequent treatment and antibiotics. Listeriosis is one such infection that can directly harm the foetus, as the organism can directly cross the placenta due to its intracellular lifecycle and is fatal to the neonate. Although salmonella spp. can cause neonatal infection in the new-borns, it is not fatal. There are such infections that can cause severe illness to the mothers, viz., E.coli, Shigellosis, Clostridiumdifficile, Cholera, Cryptosporidiumspp. Giardia amblia, and Entamoeba spp. In general, pregnant women are susceptible to constipation, diarrhoea, faecal incontinence, and haemorrhoids due to various structural, hormonal and lifestyle changes during pregnancy. Hyperemesis Gravid arum or morning sickness affects about 90% of all pregnant women and can be controlled through proper hydration and nutrition. However, if the condition is severe, hospitalization may be required as women are at risk of getting dehydrated and malnourished.
Track 9: Gall Bladder Diseases
Gallstones may create in the gallbladder and in addition somewhere else in the biliary tract. On the off chance that gallstones in the gallbladder are symptomatic, surgical evacuation of the gallbladder, known as cholecystectomy might be indicated. Gallstones frame when the shaky adjust of solvency of biliary lipids tips for precipitation of cholesterol, unconjugated bilirubin, or bacterial debasement results of biliary lipids. For cholesterol gallstones, metabolic adjustments in hepatic cholesterol discharge join with changes in gallbladder motility and intestinal bacterial corruption of bile salts to destabilize cholesterol bearers in bile and deliver cholesterol precious stones. For dark colour gallstones, changes in heme digestion or bilirubin ingestion prompt expanded bilirubin fixations and precipitation of calcium Bilirubinate. Interestingly, mechanical check of the biliary tract is the main consideration prompting bacterial debasement and precipitation of biliary lipids in dark coloured shade stones.
Track 10: Hepatitis A, D & E
Hepatitis A is an acute infection of the liver caused by the hepatitis A virus. Vaccination against hepatitis A is available. Hepatitis D is a liver disease caused by the hepatitis D virus, (also called delta virus) a defective virus that needs the hepatitis B virus to exist. Infection with hepatitis D can be prevented by hepatitis B vaccine. Hepatitis E is an acute illness but does not cause a chronic infection. It is transmitted via the faecal-oral route and can be spread by eating or drinking contaminated food or water.
Track 11: Hepatitis B
Hepatitis B is a liver infection caused by the Hepatitis B virus (HBV). HBV is transmitted through activities that involve percutaneous or mucosal contact with infectious blood or body fluids. HBV can survive outside the body at least 7 days and still be capable of causing infection. The best way to prevent hepatitis B is by getting the hepatitis B vaccine. The pathogenesis and clinical manifestations of hepatitis B are due to the interaction of the virus and the host immune system, which lead to liver injury and potentially cirrhosis and hepatocellular carcinoma. Patients can have either an acute symptomatic disease or an asymptomatic disease.
Track 12: Hepatitis C
Hepatitis C is a devastating viral disease that generally progresses slowly, meaning patients often remain asymptomatic and unaware they are infected until very serious and often expensive complications emerge as a result of damage to the liver. It is estimated that about half of those infected are not aware that they carry the virus. The recent remarkable advances in treating hepatitis C built on incremental improvements achieved over the previous two decades to transform hepatitis C from a chronic, fatal disease, to an infection that with new and forthcoming treatments, can be potentially cured.
Track 13: Non- Viral Hepatitis
Non-viral hepatitis is an inflammation of the liver caused by toxins, drugs, or other harmful chemicals that destroy cells in the liver (Hepatocytes). Acute hepatitis damages hepatocytes make up 70-85% of the total mass of the liver. The disease is a growing problem due to the increasing number of dietary supplements with liver side effects. If hepatitis leads to liver failure, a liver transplant is the only treatment option that can improve survival.
Track 14: Gastrointestinal Bleeding
Gastrointestinal (GI) bleeding is also referred to as upper, lower, obscure or occult. Upper GI bleeding commonly presents with hematemesis (vomiting of red blood), coffee-ground emesis and/or melena (black, tarry stools). The black colour of melena is the result of degradation of blood by intestinal bacteria. In comparison, the common sign of lower GI bleeding is hematochezia (bright red or maroon-coloured blood per rectum). Due to the overflow of blood through the gut, it can lead to hematochezia. Upper GI bleeding occurs proximal to the ligament of Treitz. Small bowel bleeding occurs from the ligament of Treitz to the distal ileum. Lower GI bleeding occurs from the terminal ileum and colon. Occult bleeding is bleeding that is not apparent to the patient. The quantity of bleeding is small so that the colour of stools is not altered. Patients may present with a positive faecal occult blood test (FOBT) result and/or iron-deficiency anaemia (IDA). Chronic loss of small amounts of blood can eventually lead to significant IDA.
Track 15: Colorectal Cancer
Colorectal cancer The Cancer which develops in the colon or the rectum, also known as the large intestine the small and large intestine is sometimes called the small and large bowel. Colorectal cancer usually develops gradually, over a period of 10 to 20 years. Most begin as a noncancerous growth called a polyp that develops on the inner lining of the colon or rectum. Colorectal cancers are due to old age and lifestyle factors. Symptoms usually appear after cancer development.
Track 16: Pancreatic Cancer
Pancreatic cancer starts the uncontrolled growth of cells in the pancreas leads to cancer development. It is divided into two major categories:
(1) The cancers which appear in the endocrine pancreas are called "islet cell" or "pancreatic neuroendocrine tumours or PNETs"
(2) The cancers of the exocrine pancreas (the part that makes enzymes). Signs and symptoms of pancreatic cancer Pain in the upper abdomen that radiates to back. Loss of appetite, Depression, Blood clots.
Track 17: Hepatocellular Carcinoma and Trans arterial Chemo Embolization
Hepatocellular carcinoma (HCC) is the most widely recognized kind of essential liver growth in grown-ups and is the most well-known reason for death in individuals with cirrhosis. It happens in the setting of incessant liver aggravation and is most firmly connected to endless viral hepatitis contamination (hepatitis B or C) or introduction to poisons, for example, liquor or Aflatoxin. Certain ailments, for example, hemochromatosis and alpha 1-antitrypsin lack, particularly increment the danger of treating HCC. Similarly, as with any malignancy, the treatment and forecast of HCC differ contingent upon the specifics of tumour histology, measure, how far growth has spread, and in general wellbeing.
Track 18: Intestinal Rehabilitation
Recovery of tactile and psychological capacity ordinarily includes techniques for retraining neural pathways or preparing new neural pathways to recapture or enhance neurocognitive working that has been reduced by infection or injury. Recovery research and practices are a prolific range for clinical neuropsychologists and others.
Track 19: Gastrointestinal tract imaging
Imaging turns out to be increasingly critical for every single clinical claim to fame, including gastroenterology. This issue is concentrating on some extremely intriguing and new utilizations of imaging techniques in liver, biliary tract, and stomach related tube pathology. Atomic imaging is a novel field in gastroenterology that utilizations fluorescently named tests to explicitly feature neoplastic sores on the premise of their sub-atomic mark. The advancement of sub-atomic imaging has been driven by the need to enhance endoscopic finding and by advance in focused treatments in gastrointestinal oncology to give individualized treatment, which concurs with advance in endoscopy methods and further scaling down of location gadgets.
Track 20: Abdominal & Primary Care
Essential care is the everyday social insurance given by a human services supplier. Ordinarily this supplier goes about as the main contact and chief purpose of proceeding with look after patients inside a medicinal services framework, and directions other pro care that the patient may need. Patients regularly get essential care from experts, for example, an essential care doctor (general professional or family doctor), and an attendant specialist.
Track 21: Gastrointestinal Surgery
Gastrointestinal surgery is a therapy for sicknesses of the parts of the body associated with digestion. It covers two specialties of general a medical procedure (upper gastrointestinal surgery and colorectal surgery). Upper gastrointestinal surgery covers a medical procedure on the stomach, throat (neck), small digestive tract, liver, gall bladder and pancreas. There is a tremendous supporting multidisciplinary bunch which joins anaesthetists, endocrinologists, gastroenterologists, examiners, oncologists, radiologists and histopathologists to play out this surgery. Surgery might be utilized to eliminate a carcinogenic or noncancerous development or harmed part of the body, like the digestive tract. It might likewise be utilized to fix an issue like a hernia (an opening or flimsy point in the mass of the mid-region). Minor surgeries are utilized to screen and analyse issues of the stomach related framework. Underneath conditions that might be treated with a surgery
• Appendicitis
• Weight misfortune
• Rectal prolapse
• Inflammatory gut sickness (Crohn’s disease and ulcerative colitis)
• Gastroesophageal reflux disease (GERD) and hiatal hernias
• Gallbladder infection
• Diverticular illness
• Colon malignant growth
Track 22: Gastrointestinal Pathology
Gastrointestinal Pathology is sub control of careful Pathology. It manages the investigation and openness of neoplastic and non-neoplastic sickness of the stomach related plot and frill organs, like the pancreas and liver. Pathology analysis is a basic determinant of future screening span and malignancy hazard, large numbers of these judgments don't bring about critical mortality for patients; hence, mistakes might be "veiled" by the restricted impact to the patient in the current setting.
World Gastroenterology-2023 highlights the theme “Expanding Current Trends in Gastroenterology & Hepatology”. It fundamentally focused on the latest technologies and explores the new research with all the sectors of gastroenterology.
Gastroenterology is an ever-advancing branch of internal medicine dealing with multiple ailments and different conditions of the gastrointestinal tract. It’s expanding knowledge and treatment with the advanced technologies adds a greater value in the GI market.
The worldwide transplantation market size was assessed at USD 23.5 billion out of 2022. Developing interest for novel tissue transplantation items and organ transplantation for the treatment of organ disappointment is a main consideration contributing toward development of the market.
Organ disappointment normally happens because of different factors like genuine injury, loss of blood, harming, drug misuse, leukaemia, sepsis, and other intense sicknesses. Interest for tissue and organ transplantation, predominantly kidney, heart, liver, and lungs, is high all around the world. Unfortunate dietary propensities, liquor utilization, absence of activity, and medication misuse are some driving reasons for organ disappointment. In this manner, interest for transplantation items is required to ascend soon.
As per different market reports, the gastrointestinal medications market was esteemed freely develop from the current $19.79 billion out of 2022 at a CAGR of 4.9% to reach $29.01 billion by 2024. The quick development of ulcerative colitis, enteritis, and incendiary on-going sicknesses and related entrails messes has expanded the interest of gastrointestinal medications, particularly; the calming, stomach settling agents, antidiarrheal, diuretics, antiemetic and enemies of nauseates, and antispasmodic, and these medications have seen a four-crease development on the lookout.
The worldwide market for gastrointestinal turmoil therapeutics and diagnostics came to $49.6 billion of every 2015. This market is relied upon to develop from almost $51.8 billion out of 2022 to $63.8 billion of every 2021 at a build yearly development pace of 4.3% from 2022-2021.
According to the exploration report, the worldwide gastrointestinal medications market is expected to be worth US$61.1 billion by 2024. By drug class, corrosive neutralizers fragment not drove previously, but on the other hand is required to stay in the main situation in the coming years.
Gastroenterology Universities in Europe:
• Trinity Collage Dublin, Ireland
• Donetsk Medical University, Ukraine
• Tartu University, Estonia
• College of Helsinki, Finland
• College of Chester, UK
• World Gastroenterology Organization, Austria
• European Association for Gastroenterology, Germany
• Exploration Centre of Gastroenterology and Hepatology, Romania
• European Society of Gastrointestinal Endoscopy, France
• Joined European Gastroenterology, Austria
• College of Gothenburg, Sweden
• Buda Health Centre, Hungary
• College Medical Centre Freiburg, Germany
• College of Camerino, Italy
• Kazan State Medical University, Russia
Gastroenterology Research Centres Europe:
• German Cancer Research Centre
• The Rome Foundation, Rome
• Community for Liver and Gastrointestinal Research
• SLO Foundation for Liver and Gastrointestinal Research, Netherlands
Gastroenterology Hospitals Europe:
• Belgian Society of Gastrointestinal Endoscopy, Belgium
• European Society of Gastrointestinal Endoscopy, Germany
• European culture of Neuro gastroenterology and Motility, Belgium
• German Society for Digestive and Metabolic Diseases, Germany
• Russian Society for Digestive Endoscopy, Russia
Gastrointestinal Therapeutics Market
The gastrointestinal therapeutics market is expected to register a healthy CAGR of nearly 6.5 % during the forecast period (2019 - 2024).
-
The market is majorly driven by the lifestyle changes, leading to gastrointestinal (GI) diseases. According to the National Health Interview Survey (2021), 15.3 million adults were diagnosed with ulcers in the United States.
-
Other driving factors include the rising surgical treatments and hospitalizations, due to GI diseases, and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars.
-
However, risk factors, such as those related to the physiological, behavioural, psychosocial, and socio-environmental aspects, restrict the populations from reporting the diseases early, which reflects the low awareness and the economic burden.
-
These risk factors and the increasing number of patent expirations restrict the growth of the gastrointestinal therapeutics market.
Inflammatory Ulcerative Colitis Holds Significant Market Share
Inflammatory ulcerative colitis (UC) is often a relapsing and remitting disease. The disease often deals with lifelong treatment therapies. However, the current treatment options have several adverse effects and poor efficacy profiles. Additionally, sometimes, the drug is highly expensive, which makes this segment lucrative for the biopharmaceutical companies. Some of the traditional classes of drugs, including 5-aminosalicylic acid, corticosteroids, and immune-modulating drugs, are helpful for inflammatory bowel disease (IBD). Biologic drugs have also been explored in the past two decades, with several being marketed, which include anti-TNF drugs, immunosuppressive interleukins, and anti-interleukin antibodies. As per Merck & Co. Inc. (2018), although diverse medication facilities exist, one-third of the overall patient population suffering from UC ultimately requires surgery. Takeda Pharmaceuticals, Jassen Pharmaceuticals, and Pfizer are among the major global companies that have established themselves with their products for the treatment of inflammatory ulcerative colitis.
Market Growth of Gastroenterology Research World Wide:
According to geology, the worldwide gastrointestinal medications showcase is required to be driven by North America. Good repayment approaches, and expanding geriatric populace, who are more inclined to gastrointestinal clutters, will drive the area's development amid the estimate time frame from 2016 to 2024. North America held 41% of the market in 2019. Europe has additionally been seeing solid development and is expected to keep being an alluring district for gastrointestinal medications showcase. "The development of biosimilars for treating incendiary inside sicknesses will likewise be a key development driver for the market in Europe," says a TMR expert. Be that as it may, Asia Pacific is evaluated to be the area with greatest open doors for development in the coming years. The developing speculations and financing in the field of life science inquire about and propelled treatments for the treatment of gastrointestinal maladies in creating countries, for example, China and India will fuel the development of the Asia Pacific market.
As per the research report, the global gastrointestinal drugs market is anticipated to be worth US$61.1 billion by 2024 and the global market for gastrointestinal medical devices will reach $18.2 billion in 2018 with nearly 25% of that consumed within gastrointestinal endoscopic devices worldwide by 2020. In addition to outstanding clinical care, GI research is also a priority and scientists currently receive more than $5 million annually in external funding to perform gastrointestinal research.
Market Growth in Canada
Fast-paced modern lifestyles, which increase the stress levels of working consumers, in particular, support the growth in sales of digestive remedies in Canada. According to the Canadian Digestive Health Foundation, digestive disorders affect more than 20 million Canadians each year. The growing rate of obesity in Canada also increases the risk of many digestive disorders, such as gastroesophageal reflux disease (GERD) and stomach ulcers. However, while obesity could lead to more consumers becoming frequent users of digestive remedies, weight loss and healthier diets may reduce the risk of some digestive problems or prevent them from progressing.
According to the report, the North America region is expected to hold the largest share in the global gastrointestinal diseases market. This dominance of North America is attributed to the rising approval of the novel drugs and the growth in the instances of various gastrointestinal diseases. While recent pharmaceutical industry trends in Canada have been challenged with poor market growth and pressures from global competition, there still remains a very viable industry which if aided by stronger industrial sector support can flourish and successfully compete in this new and much more globally competitive business environment. Canada also has an opportunity to be a global leader in certain new growth areas.
